Life Technologies Ion AmpliSeq BRCA1 and BRCA2 Panel and Ion AmpliSeq Colon and Lung Cancer Panel

Life Technologies Corporation has launched two Ion AmpliSeq Community Panels: the Ion AmpliSeq BRCA1 and BRCA2 Panel design and the Ion AmpliSeq Colon and Lung Cancer Panel design. The panels require just 10 ng of DNA input per primer pool, about 25-fold less than alternative gene panel approaches. The workflow is a simple PCR reaction coupled with rapid ion semiconductor sequencing, enabling researchers to go from DNA to results in less than 24 h.

The BRCA panel analyses the coding regions of the tumour suppressor genes BRCA1 and BRCA2, which have been implicated in hereditary breast and ovarian cancers. The colon and lung panel analyses more than 500 mutations in 22 associated genes. The panels can accurately call all variants of interest, including those within difficult sequence contexts.

The Ion AmpliSeq Colon and Lung Cancer Panel design analyses more than 500 mutations in a single-tube assay. The workflow can be completed in as few as 3.5 h turnaround time. The panel design permits the user to describe a cancer according to the molecular subpopulation that compose the lesion; something said to be impossible with previous methods.